电子药物输送设备市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球电子给药设备市场价值为 647 亿美元，预计到 2034 年将以 8.5% 的复合年增长率成长，达到 1,460 亿美元。这些设备是先进的系统，旨在透过使用者手动启动或自动编程以电子方式管理药物，并且通常会记录剂量事件以供监测和遵守。该技术与即时连接的传感器和微处理器集成，从而能够根据预设的治疗方案和即时生理资料提供精确的个人化药物。与可能存在依从性问题的传统药物传递方法不同，电子设备提供可程式化、准确且以患者为中心的药物解决方案。

这不仅可以透过持续给药来改善治疗效果，还有助于降低住院和监测成本，这对于高收入和资源受限的医疗保健环境都极具价值。老年人口的成长，往往伴随着癌症、心血管疾病、糖尿病和慢性肾臟病等慢性疾病，是推动电子药物传递系统需求的重要因素，因为这些患者需要持续、方便的治疗。

2024年，植入式药物传输设备领域占据市场主导地位，占33.6%。随着癌症、糖尿病和心臟病等慢性疾病的日益流行，对长期可控药物传输系统的需求显着增长。化疗输液港和标靶输送系统等植入式设备可以减少不遵从性并改善临床疗效。可程式帮浦、标靶药物洗脱植入物和可生物降解植入物的需求也正在扩展到其他治疗领域，包括疼痛管理和神经病学。

2024年，糖尿病领域占了33.9%的市场。全球糖尿病病例的不断增长推动了对先进胰岛素帮浦和贴片注射器等设备的需求，这些设备能够持续监测血糖并自动输送胰岛素。此外，监管部门的批准和支持性报销政策使得糖尿病电子给药系统更加普及，促进了其普及。

2024年，美国电子给药设备市场规模达251亿美元。随着人口老化和慢性病发病率持续上升，美国对电子给药设备的需求预计将持续成长。受远端门诊监控、医疗支出成长以及价值导向医疗模式转变的推动，先进的自动注射器、数位吸入器和智慧型穿戴式输液帮浦的普及率不断提升。美国完善的数位医疗基础设施进一步支持了互联医疗系统的整合，从而进一步推动了此类设备市场的发展。

全球电子给药设备市场的主要参与者包括 Becton、Dickinson and Company、辉瑞、美敦力、Insulet、West Pharmaceutical Services、礼来公司、诺和诺德、Tandem Diabetes Care、Gerresheimer、Ypsomed、阿斯特捷利康、雅培实验室、SHL 集团、Nemera 和赛诺菲诺菲诺。在电子给药设备市场中营运的公司采用各种策略来加强其影响力。许多公司专注于技术创新，例如开发具有即时资料功能、更精确、用户友好的设备。这些公司还透过提供跨多个治疗领域的解决方案来扩展其产品组合，包括糖尿病和心血管疾病等慢性疾病。与医疗服务提供者和监管机构建立策略合作伙伴关係有助于加快审批并确保更广泛的市场准入。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
  • 供应商格局
  • 每个阶段的增值
  • 影响价值链的因素
• 产业衝击力
  • 成长动力
    • 慢性病发生率上升
    • 越来越倾向于家庭医疗保健解决方案
    • 数位整合的进步和个人化治疗意识的提高
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 先进药物传输装置成本高昂
    • 患者意识低下和设备相关併发症
  • 市场机会
    • 向医疗基础设施有限的新兴市场扩张
    • 人工智慧与分析的整合，实现个人化剂量
• 成长潜力分析
• 监管格局
• 波特的分析
• PESTEL分析
• 技术和创新格局
  • 当前的技术趋势
  • 新兴技术
• 价格趋势
  • 按地区
  • 按产品
• 未来市场趋势
• 技术和创新格局
  • 当前的技术趋势
  • 新兴技术
• 报销场景
  • 报销政策对市场成长的影响
• 专利格局
• 消费者行为分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係和合作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 智慧型输液帮浦
• 智慧定量吸入器
• 植入式药物传输装置
• 智慧透皮贴片
• 其他产品

第六章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 糖尿病
• 呼吸系统疾病
• 肿瘤学
• 心臟病学
• 其他应用

第七章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋

第八章：公司简介

• Abbott Laboratories
• AstraZeneca
• Becton, Dickinson and Company
• Eli Lilly and Company
• Gerresheimer
• Haselmeier
• Insulet
• Medtronic
• Nemera
• Novo Nordisk
• Pfizer
• Sanofi
• SHL Group
• Tandem Diabetes Care
• West Pharmaceutical Services
• Ypsomed

The Global Electronic Drug Delivery Devices Market was valued at USD 64.7 billion in 2024 and is estimated to grow at a CAGR of 8.5% to reach USD 146 billion by 2034. These devices are advanced systems designed to administer medication electronically, either through manual initiation by the user or automatic programming, and often record dosage events for monitoring and compliance. The technology is integrated with sensors and microprocessors that connect in real-time, enabling the delivery of precise, individualized medication based on pre-set therapeutic protocols and real-time physiological data. Unlike traditional drug delivery methods, which may suffer from adherence issues, electronic devices offer programmable, accurate, and patient-focused medication solutions.

This not only improves treatment outcomes through consistent dosing but also helps reduce hospitalization and monitoring costs, which is valuable in both high-income and resource-constrained healthcare settings. The growing elderly population, who often face chronic diseases like cancer, cardiovascular conditions, diabetes, and chronic kidney disease, is a significant factor driving the demand for electronic drug delivery systems, as these patients require continuous, user-friendly treatments.

The implantable drug delivery devices segment led the market in 2024, accounting for 33.6% share. With the increasing prevalence of chronic diseases like cancer, diabetes, and heart conditions, the demand for long-term, controlled drug delivery systems has grown significantly. Implantable devices, such as chemotherapy ports and targeted delivery systems, reduce non-compliance and enhance clinical outcomes. The demand for programmable pumps, targeted drug-eluting implants, and biodegradable implants is also expanding into other therapeutic areas, including pain management and neurology.

In 2024, the diabetes segment represented 33.9% share. The rising number of diabetes cases worldwide has driven demand for devices like advanced insulin pumps and patch injectors that offer continuous glucose monitoring and automatic insulin delivery. Furthermore, regulatory approvals and supportive reimbursement policies have made electronic drug delivery systems for diabetes more widely accessible, boosting adoption.

U.S. Electronic Drug Delivery Devices Market was valued at USD 25.1 billion in 2024. As the population ages and chronic diseases continue to rise, the demand for electronic drug delivery devices in the U.S. is expected to grow. The adoption of advanced autoinjectors, digital inhalers, and smart wearable infusion pumps has increased, driven by remote outpatient monitoring, rising healthcare spending, and a shift toward value-based care. The well-established digital health infrastructure in the U.S. further supports the integration of connected medical systems, which fuels the market for these devices.

Major players in the Global Electronic Drug Delivery Devices Market include Becton, Dickinson and Company, Pfizer, Medtronic, Insulet, West Pharmaceutical Services, Eli Lilly and Company, Novo Nordisk, Tandem Diabetes Care, Gerresheimer, Ypsomed, AstraZeneca, Abbott Laboratories, SHL Group, Nemera, and Sanofi. Companies operating in the electronic drug delivery devices market employ various strategies to strengthen their presence. Many are focusing on technological innovation, such as the development of more precise, user-friendly devices with real-time data capabilities. These companies are also expanding their portfolios by offering solutions across multiple therapeutic areas, including chronic diseases like diabetes and cardiovascular conditions. Strategic partnerships with healthcare providers and regulatory bodies help expedite approvals and ensure broader market access.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product
  • 2.2.3 Application
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases
    • 3.2.1.2 Increasing inclination toward home-based healthcare solutions
    • 3.2.1.3 Advancements in digital integration and heightened awareness around personalized therapeutics
    • 3.2.1.4 Growing geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced drug delivery devices
    • 3.2.2.2 Low patient awareness and device-related complications
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion into emerging markets with limited healthcare infrastructure
    • 3.2.3.2 Integration of AI and analytics for personalized dosing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Technology and innovation landscape
  • 3.7.1 Current technological trends
  • 3.7.2 Emerging technologies
• 3.8 Price trends
  • 3.8.1 By region
  • 3.8.2 By product
• 3.9 Future market trends
• 3.10 Technology and innovation landscape
  • 3.10.1 Current technological trends
  • 3.10.2 Emerging technologies
• 3.11 Reimbursement scenario
  • 3.11.1 Impact of reimbursement policies on market growth
• 3.12 Patent landscape
• 3.13 Consumer behaviour analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Smart infusion pumps
• 5.3 Smart metered dose inhalers
• 5.4 Implantable drug delivery devices
• 5.5 Smart transdermal patches
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetes
• 6.3 Respiratory diseases
• 6.4 Oncology
• 6.5 Cardiology
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 India
  • 7.4.3 Japan
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 South Africa
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 AstraZeneca
• 8.3 Becton, Dickinson and Company
• 8.4 Eli Lilly and Company
• 8.5 Gerresheimer
• 8.6 Haselmeier
• 8.7 Insulet
• 8.8 Medtronic
• 8.9 Nemera
• 8.10 Novo Nordisk
• 8.11 Pfizer
• 8.12 Sanofi
• 8.13 SHL Group
• 8.14 Tandem Diabetes Care
• 8.15 West Pharmaceutical Services
• 8.16 Ypsomed